What this Trial Is About

The incidence of skin cancer, including non-melanoma and melanoma types, has been rising steadily over recent decades. Traditional diagnosis relies on invasive biopsy and histological examination, but new imaging technologies like reflectance confocal microscopy (RCM) and optical coherence tomography (OCT) are being explored to improve diagnosis accuracy and reduce unnecessary biopsies. This research evaluates a novel high-resolution OCT scanner called the ApolloVueAE S100 Image System, which provides detailed cellular-level images of pigmented and non-pigmented skin tumors, aiming to advance non-invasive skin cancer diagnosis. The study uses the ApolloVueAE S100 System, a CE-certified device that captures two-dimensional cross-sectional and en-face images of the skin in real time. This system combines vertical and horizontal evaluation at a depth of around 400 micrometers with cellular resolution and offers fast scanning speeds without depth-of-field limitations. Participants' skin lesions will also be imaged using other devices such as VivascopeAE confocal microscopy, VivosightAE optical coherence tomography, and DermLite FotoXAE dermoscopy for comparison and evaluation of a subset of lesions. During the 1.5-year study, participants will undergo high-resolution OCT imaging and other non-invasive scans to assess their skin lesions. The study will record images and lesion positions for follow-up and monitor disease features of pigmented and non-pigmented skin lesions. Researchers will evaluate the detailed skin structures captured and compare imaging results to improve diagnosis accuracy. Participants' involvement includes skin lesion imaging, data collection, and image management throughout the study.

Applicability of a Cellular Resolution Full-field OCT Image System for Pigmented and Non-pigmented Skin Tumors